Literature DB >> 6576830

Prodrugs and outpatient medical practice.

C Scoggin.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6576830      PMCID: PMC1911664     

Source DB:  PubMed          Journal:  Bull N Y Acad Med        ISSN: 0028-7091


× No keyword cloud information.
  7 in total

1.  Rationale for design of biologically reversible drug derivatives: prodrugs.

Authors:  A A Sinkula; S H Yalkowsky
Journal:  J Pharm Sci       Date:  1975-02       Impact factor: 3.534

2.  Sinusitis of the maxillary antrum.

Authors:  F O Evans; J B Sydnor; W E Moore; G R Moore; J L Manwaring; A H Brill; R T Jackson; S Hanna; J S Skaar; L V Holdeman; S Fitz-Hugh; M A Sande; J M Gwaltney
Journal:  N Engl J Med       Date:  1975-10-09       Impact factor: 91.245

Review 3.  Role of infection in chronic bronchitis.

Authors:  I Tager; F E Speizer
Journal:  N Engl J Med       Date:  1975-03-13       Impact factor: 91.245

4.  Tissue levels after administration of bacampicillin, a prodrug of ampicillin, and comparisons with other aminopenicillins: a review.

Authors:  J Sjövall
Journal:  J Antimicrob Chemother       Date:  1981-11       Impact factor: 5.790

5.  Esters of N-tert-butylarterenol. Long-acting new bronchodilators with reduced cardiac effects.

Authors:  B F Tullar; H Minatoya; R R Lorenz
Journal:  J Med Chem       Date:  1976-06       Impact factor: 7.446

6.  Studies on bitolterol, di-p-toluate ester of N-tert.-butylarterenol: a new long-acting bronchodilator with reduced cardiovascular effects.

Authors:  H Minatoya
Journal:  J Pharmacol Exp Ther       Date:  1978-09       Impact factor: 4.030

7.  Bitolterol mesylate (WIN 32784) aerosol. A new long-acting bronchodilator with reduced chronotropic effects.

Authors:  I Kass; T S Mingo
Journal:  Chest       Date:  1980-08       Impact factor: 9.410

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.